New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 10, 2014
12:29 EDTMNKDMannKind retreats after potential rival starts IPO process
Shares of drug maker MannKind (MNKD) are falling after a potential competitor, Dance Biopharm, sought to launch an initial public offering. WHAT'S NEW: Dance Biopharm filed papers with the SEC to raise $75M through an IPO last night. Like Mannkind, Dance has developed an inhaled insulin product that is supposed to treat diabetes. Dance's lead product, Dance 501, is designed to deliver liquid insulin through a small, handheld electronic inhaler, Dance stated in its IPO application. The company plans to launch a Phase III trial of the product in early 2015 and eventually seek regulatory approval of the product in the EU, U.S., and China. MannKind's AFREZZA, which is designed to deliver insulin through an inhaler, is currently under review for approval by the FDA. PRICE ACTION: In early afternoon trading, MannKind sank 30c, or 4.3%, to $6.70.
News For MNKD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2015
05:36 EDTMNKDStocks with implied volatility movement; MNKD ABT
Subscribe for More Information
August 27, 2015
05:54 EDTMNKDStocks with implied volatility above IV index mean; MNKD AMBA
Subscribe for More Information
August 26, 2015
05:52 EDTMNKDStocks with implied volatility movement; TSM MNKD
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use